Key Highlights
- Third-quarter 2026 Revenue was USD 72.9 million, against USD 46.3 million a year earlier.
- Gross profit was USD 60.9 million; net loss was USD 11.5 million.
- Management raised its full-year revenue outlook to USD 262 million to USD 264 million.
- Cash, cash equivalents and investments were USD 253.0 million at September 30, 2026.
Heartflow (NASDAQ:HTFL) reported third-quarter 2026 revenue of USD 72.9 million, against an estimate of USD 65.19 million and USD 46.3 million in the prior-year quarter. Net loss was USD 11.5 million, or USD 0.13 per share. President and Chief Executive Officer John Farquhar said revenue rose 57% year over year, with U.S. revenue up 60%, which he described as the company's fastest U.S. growth in 11 quarters.
Quarterly Results
Revenue was USD 72.9 million, against USD 46.3 million. For the nine months, revenue was USD 189.5 million, against USD 126.9 million. Cost of revenue was USD 11.9 million, against USD 10.9 million, and Gross Profit was USD 60.9 million, against USD 35.4 million. Gross profit for the nine months was USD 156.3 million, against USD 96.1 million.
Research and development expenses were USD 29.5 million, against USD 17.3 million, and selling, general and administrative expenses were USD 45.3 million, against USD 33.2 million. Total operating expenses were USD 74.8 million, against USD 50.5 million, and the loss from operations was USD 13.8 million, against USD 15.1 million.
Interest income was USD 2.3 million, against USD 1.7 million, while the prior-year quarter included interest expense of USD 3.5 million, a USD 32.1 million change in Fair Value of a common stock Warrant Liability and a USD 6.4 million loss on extinguishment of debt. Net loss was USD 11.5 million, against USD 50.9 million, and net loss per share was USD 0.13, against USD 1.04. For the nine months, net loss was USD 54.6 million, or USD 0.63 per share.
Commercial Drivers and Outlook
Farquhar named four factors behind the quarter: continued Plaque adoption, durable FFRCT utilization across existing accounts, strong new account additions, including continued ramp of the 340 accounts added in 2025, and growth in the coronary CT angiography market. He said coronary CT angiography is only 11% penetrated of the noninvasive testing market. The filing states that 36% of U.S. revenue cases were attributable to office and clinic-based accounts, against 32% a year earlier.
Management raised its full-year total revenue outlook to USD 262 million to USD 264 million, up 49% to 50% year over year, and raised its Plaque revenue outlook to USD 36 million to USD 37 million. It said it now projects approximately 1,300 Plaque active accounts by year-end, and raised its non-GAAP gross Margin guidance to approximately 82.5%. Management also said it now projects 2026 new account activations to exceed the 340 added in 2025, and reiterated a midterm non-GAAP gross margin target of 85%.
Balance Sheet
As of September 30, 2026, the company had USD 253.0 million in cash, cash equivalents and investments. Total Assets were USD 355.3 million, against USD 359.5 million at December 31, 2025, and total stockholders' Equity was USD 282.5 million, against USD 300.6 million. The accumulated Deficit was USD 1,142.4 million, against USD 1,087.8 million.
The filing reports an increase of USD 18.9 million in Accounts Receivable and a USD 5.5 million increase in prepaid expenses and other current assets as drivers of the change in net operating assets for the nine months. The company recorded an asset Impairment charge of USD 7.5 million in the nine-month period. Weighted-average shares used to compute net loss per share were 87,249,228 for the quarter, against 49,106,752 a year earlier.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...